MX342131B - Eliminacion selectiva de celulas erosivas. - Google Patents

Eliminacion selectiva de celulas erosivas.

Info

Publication number
MX342131B
MX342131B MX2013014203A MX2013014203A MX342131B MX 342131 B MX342131 B MX 342131B MX 2013014203 A MX2013014203 A MX 2013014203A MX 2013014203 A MX2013014203 A MX 2013014203A MX 342131 B MX342131 B MX 342131B
Authority
MX
Mexico
Prior art keywords
selective elimination
erosive
cells
treatment
erosive cells
Prior art date
Application number
MX2013014203A
Other languages
English (en)
Other versions
MX2013014203A (es
Inventor
Söderström Kalle
Douglas Galsgaard Elizabeth
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2013014203A publication Critical patent/MX2013014203A/es
Publication of MX342131B publication Critical patent/MX342131B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un anticuerpo anti-NXG2A, o un fragmento de enlace a antígeno del mismo, para usarse en el tratamiento de un paciente que tiene destrucción de cartílago y/o erosión ósea, en donde el anticuerpo anti-NKG2A estimula la eliminación selectiva de células destructivas de cartílago y/o reduce la formación de células que erosinan el hueso.
MX2013014203A 2011-06-17 2012-06-18 Eliminacion selectiva de celulas erosivas. MX342131B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11170402 2011-06-17
US201161501533P 2011-06-27 2011-06-27
PCT/EP2012/061583 WO2012172102A1 (en) 2011-06-17 2012-06-18 Selective elimination of erosive cells

Publications (2)

Publication Number Publication Date
MX2013014203A MX2013014203A (es) 2014-01-20
MX342131B true MX342131B (es) 2016-09-14

Family

ID=44904625

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014203A MX342131B (es) 2011-06-17 2012-06-18 Eliminacion selectiva de celulas erosivas.

Country Status (11)

Country Link
US (4) US9512228B2 (es)
EP (1) EP2721068B1 (es)
JP (1) JP6334395B2 (es)
KR (1) KR102047248B1 (es)
CN (1) CN103635487B (es)
AU (1) AU2012268939B2 (es)
BR (1) BR112013032217B1 (es)
CA (1) CA2838220C (es)
MX (1) MX342131B (es)
RU (1) RU2617056C2 (es)
WO (1) WO2012172102A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007935A (es) 2004-12-28 2007-12-06 Innate Pharma Sa Anticuerpos monoclonales contra nkg2a.
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
MX342131B (es) 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
HRP20201656T1 (hr) 2014-09-16 2021-03-05 Innate Pharma Neutralizacija inhibitornih putova u limfocitima
WO2016041947A1 (en) * 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
JP6889660B2 (ja) 2014-10-23 2021-06-18 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 抗ｎｋｇ２ａ剤を用いた癌の処置
PL3405495T3 (pl) 2016-01-21 2021-10-11 Innate Pharma Neutralizacja szlaków inhibitorowych w limfocytach
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
TW202003582A (zh) 2018-03-13 2020-01-16 法商天賜製藥公司 頭頸癌之治療
CA3099820A1 (en) 2018-05-15 2019-11-21 Medimmune Limited Treatment of cancer
EP3946455A4 (en) * 2019-03-29 2022-12-21 Dren Bio, Inc. METHOD OF REDUCING THE CONCENTRATION OF LARGE GRANULAR LYMPHOCYTES AND NATURAL KILLER CELLS
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
US11795228B2 (en) 2020-09-30 2023-10-24 Dren Bio, Inc. Anti-CD94 antibodies and methods of use thereof
CN114524876B (zh) * 2020-11-23 2025-12-05 南京北恒生物科技有限公司 靶向nkg2a的抗体及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH03112486A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112487A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞
JPH03112485A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112484A (ja) 1989-09-26 1991-05-14 Nisshin Seito Kk 新規制限酵素及びその製造方法
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH03112484U (es) 1990-03-02 1991-11-18
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
US20040038339A1 (en) 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US6999941B1 (en) 2000-07-11 2006-02-14 Amazon.Com, Inc. Providing gift clustering functionality to assist a user in ordering multiple items for a recipient
JP2004528824A (ja) 2000-12-18 2004-09-24 アーンスティテュ ナシオナール ド ラ サント エ ド ラ ルシェルシェ メディカル（イー．エンヌ．エス．ウー．エール．エンム．） 皮膚ｔ細胞リンパ腫（ｃｔｃｌ）の新規な診断及び治療法
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
CA2454185A1 (en) 2001-07-19 2003-01-30 Innate Pharma Ntb-a, a surface molecule involved in natural killer cells activity
US20030171280A1 (en) 2001-07-31 2003-09-11 Soderstrom Karl Petter Compositions and methods for modulation of immune responses
AU2003233894A1 (en) 2002-05-13 2003-11-11 Envirotech Products Limited Tank valve testing method
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
CN1748143A (zh) 2002-12-16 2006-03-15 健泰科生物技术公司 表达人cd20和/或cd16的转基因小鼠
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
EP2292264A3 (en) 2003-07-24 2012-12-19 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
WO2005105849A1 (en) 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for treating proliferative disorders such as nk-type ldgl
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
CN101107269B (zh) 2004-12-28 2012-10-31 依奈特制药公司 抗nkg2a的单克隆抗体
MX2007007935A (es) * 2004-12-28 2007-12-06 Innate Pharma Sa Anticuerpos monoclonales contra nkg2a.
JP5419067B2 (ja) * 2005-10-14 2014-02-19 イナート・ファルマ・ソシエテ・アノニム 増殖性障害を処置するための組成物および方法
AU2007276294B2 (en) 2006-06-30 2012-11-29 Novo Nordisk A/S Anti-NKG2A antibodies and uses thereof
CN101952317B (zh) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
MX342131B (es) * 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
RU2017105425A (ru) 2014-08-28 2018-09-28 Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
WO2016041947A1 (en) 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
HRP20201656T1 (hr) 2014-09-16 2021-03-05 Innate Pharma Neutralizacija inhibitornih putova u limfocitima
JP6889660B2 (ja) 2014-10-23 2021-06-18 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 抗ｎｋｇ２ａ剤を用いた癌の処置
PL3405495T3 (pl) 2016-01-21 2021-10-11 Innate Pharma Neutralizacja szlaków inhibitorowych w limfocytach

Also Published As

Publication number Publication date
BR112013032217A2 (pt) 2016-11-22
US20200109206A1 (en) 2020-04-09
US20170073417A1 (en) 2017-03-16
RU2617056C2 (ru) 2017-04-19
CA2838220C (en) 2020-07-21
EP2721068A1 (en) 2014-04-23
BR112013032217B1 (pt) 2021-01-19
CA2838220A1 (en) 2012-12-20
MX2013014203A (es) 2014-01-20
CN103635487B (zh) 2016-10-12
EP2721068B1 (en) 2018-12-05
JP2014519522A (ja) 2014-08-14
KR20140037918A (ko) 2014-03-27
KR102047248B1 (ko) 2019-11-21
RU2013158625A (ru) 2015-07-27
CN103635487A (zh) 2014-03-12
JP6334395B2 (ja) 2018-05-30
US20140161802A1 (en) 2014-06-12
WO2012172102A1 (en) 2012-12-20
US11697687B2 (en) 2023-07-11
US9512228B2 (en) 2016-12-06
US20230416374A1 (en) 2023-12-28
AU2012268939B2 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
MX342131B (es) Eliminacion selectiva de celulas erosivas.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
PH12018501376A1 (en) Processing biomass and energy
MX2017007538A (es) Sintesis de ácido nucleíco de volúmen pequeño, alta eficiencia.
MX2019003616A (es) Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas.
MX2014001383A (es) Colageno 7 y metodos relacionados.
BR112013032229A2 (pt) método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição
MY160608A (en) APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS
TN2015000353A1 (en) Newcastle disease viruses and uses thereof
AU331234S (en) Insulated bottle
EA201490886A1 (ru) Переработка биомассы
PH12013500703A1 (en) Human oncostatin m antibodies and methods of use
GT201200011A (es) Diferenciación de células madre mesenquimales
NZ717399A (en) Antibodies against csf-1r
WO2010107914A3 (en) Biomass production and processing and methods of use thereof
UY34185A (es) ?partículas cristalinas recubiertas con micelas de copolímeros, composiciones, proceso de preparación de dichas partículas y sus usos?.
FI20115328A0 (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
PH12013500500A1 (en) Fused heteroaryls and their uses
PL3013758T3 (pl) Instalacja do przetwarzania i odzyskiwania odpadów pochodzących od zwierząt hodowlanych obejmująca metanizację, kultury mikroalg i makrofitów oraz wermikulturę
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
BR112014011254A2 (pt) 2-tiopirimidinonas
MY155330A (en) Methods for salt production
PH12016501191A1 (en) Ras opposite (rop) and related nucleic acid molecules that confer resistance to coleopteran and/or hemipteran pests
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
IN2014DN00254A (es)

Legal Events

Date Code Title Description
FG Grant or registration